STUDY OBJECTIVES: The attenuation of heart rate recovery after maximal exercise (ΔHRR) is independently impaired by obstructive sleep apnea (OSA) and metabolic syndrome (MetS). Therefore, we tested the hypotheses: (1) MetS + OSA restrains ΔHRR; and (2) Sympathetic hyperactivation is involved in this impairment. DESIGN: Cross-sectional study. PARTICIPANTS: We studied 60 outpatients in whom MetS had been newly diagnosed (ATP III), divided according to apnea-hypopnea index (AHI) ≥ 15 events/h in MetS + OSA (n = 30, 49 ± 1.7 y) and AHI < 15 events/h in MetS - OSA (n = 30, 46 ± 1.4 y). Normal age-matched healthy control subjects (C) without MetS and OSA were also enrolled (n = 16, 46 ± 1.7 y). INTERVENTIONS: Polysomnography, microneurography, cardiopulmonary exercise test. MEASUREMENTS AND RESULTS: We evaluated OSA (AHI - polysomnography), muscle sympathetic nerve activity (MSNA - microneurography) and cardiac autonomic activity (LF = low frequency, HF = high frequency, LF/HF = sympathovagal balance) based on spectral analysis of heart rate (HR) variability. ΔHRR was calculated (peak HR minus HR at first, second, and fourth minute of recovery) after cardiopulmonary exercise test. MetS + OSA had higher MSNA and LF, and lower HF than MetS - OSA and C. Similar impairment occurred in MetS - OSA versus C (interaction, P < 0.01). MetS + OSA had attenuated ΔHRR at first, second, and at fourth minute than did C, and attenuated ΔHRR at fourth minute than did MetS - OSA (interaction, P < 0.001). Compared with C, MetS - OSA had attenuated ΔHRR at second and fourth min (interaction, P < 0.001). Further analysis showed association of the ΔHRR (first, second, and fourth minute) and AHI, MSNA, LF and HF components (P < 0.05 for all associations). CONCLUSIONS: The attenuation of heart rate recovery after maximal exercise is impaired to a greater degree where metabolic syndrome (MetS) is associated with moderate to severe obstructive sleep apnea (OSA) than by MetS with no or mild or no OSA. This is at least partly explained by sympathetic hyperactivity.
STUDY OBJECTIVES: The attenuation of heart rate recovery after maximal exercise (ΔHRR) is independently impaired by obstructive sleep apnea (OSA) and metabolic syndrome (MetS). Therefore, we tested the hypotheses: (1) MetS + OSA restrains ΔHRR; and (2) Sympathetic hyperactivation is involved in this impairment. DESIGN: Cross-sectional study. PARTICIPANTS: We studied 60 outpatients in whom MetS had been newly diagnosed (ATP III), divided according to apnea-hypopnea index (AHI) ≥ 15 events/h in MetS + OSA (n = 30, 49 ± 1.7 y) and AHI < 15 events/h in MetS - OSA (n = 30, 46 ± 1.4 y). Normal age-matched healthy control subjects (C) without MetS and OSA were also enrolled (n = 16, 46 ± 1.7 y). INTERVENTIONS: Polysomnography, microneurography, cardiopulmonary exercise test. MEASUREMENTS AND RESULTS: We evaluated OSA (AHI - polysomnography), muscle sympathetic nerve activity (MSNA - microneurography) and cardiac autonomic activity (LF = low frequency, HF = high frequency, LF/HF = sympathovagal balance) based on spectral analysis of heart rate (HR) variability. ΔHRR was calculated (peak HR minus HR at first, second, and fourth minute of recovery) after cardiopulmonary exercise test. MetS + OSA had higher MSNA and LF, and lower HF than MetS - OSA and C. Similar impairment occurred in MetS - OSA versus C (interaction, P < 0.01). MetS + OSA had attenuated ΔHRR at first, second, and at fourth minute than did C, and attenuated ΔHRR at fourth minute than did MetS - OSA (interaction, P < 0.001). Compared with C, MetS - OSA had attenuated ΔHRR at second and fourth min (interaction, P < 0.001). Further analysis showed association of the ΔHRR (first, second, and fourth minute) and AHI, MSNA, LF and HF components (P < 0.05 for all associations). CONCLUSIONS: The attenuation of heart rate recovery after maximal exercise is impaired to a greater degree where metabolic syndrome (MetS) is associated with moderate to severe obstructive sleep apnea (OSA) than by MetS with no or mild or no OSA. This is at least partly explained by sympathetic hyperactivity.
Authors: G Grassi; R Dell'Oro; F Quarti-Trevano; F Scopelliti; G Seravalle; F Paleari; P L Gamba; G Mancia Journal: Diabetologia Date: 2005-06-03 Impact factor: 10.122
Authors: Jonathan Myers; Manish Prakash; Victor Froelicher; Dat Do; Sara Partington; J Edwin Atwood Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245
Authors: M M Ribeiro; I C Trombetta; L T Batalha; M U Rondon; C L Forjaz; A C Barretto; S M Villares; C E Negrão Journal: Braz J Med Biol Res Date: 2001-04 Impact factor: 2.590
Authors: Steven R Coughlin; Lynn Mawdsley; Julie A Mugarza; Peter M A Calverley; John P H Wilding Journal: Eur Heart J Date: 2004-05 Impact factor: 29.983
Authors: M Pagani; F Lombardi; S Guzzetti; O Rimoldi; R Furlan; P Pizzinelli; G Sandrone; G Malfatto; S Dell'Orto; E Piccaluga Journal: Circ Res Date: 1986-08 Impact factor: 17.367
Authors: Germana P L Almeida; Ivani C Trombetta; Felipe X Cepeda; Elaine Hatanaka; Rui Curi; Cristiano Mostarda; Maria C Irigoyen; José A S Barreto-Filho; Eduardo M Krieger; Fernanda M Consolim-Colombo Journal: Front Physiol Date: 2017-01-23 Impact factor: 4.566
Authors: Felipe X Cepeda; Leslie Virmondes; Sara Rodrigues; Akothirene C B Dutra-Marques; Edgar Toschi-Dias; Fernanda C Ferreira-Camargo; Maria Fernanda Hussid; Maria Urbana Pb Rondon; Maria Janieire N N Alves; Ivani C Trombetta Journal: PLoS One Date: 2019-05-21 Impact factor: 3.240
Authors: Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Akothirene C B Dutra-Marques; Jefferson C Carvalho; Valéria Costa-Hong; Maria Janieire N N Alves; Maria Urbana P B Rondon; Luiz A Bortolotto; Ivani C Trombetta Journal: J Clin Hypertens (Greenwich) Date: 2017-09-04 Impact factor: 3.738
Authors: Akothirene C Dutra-Marques; Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Eduardo Rondon; Jefferson C Carvalho; Maria Janieire N N Alves; Ana Maria F W Braga; Maria Urbana P B Rondon; Ivani C Trombetta Journal: Front Neurosci Date: 2021-06-09 Impact factor: 4.677